NATCOPHARM - Swing Trade Analysis with AI Signals
Back to ListHere’s the structured swing trade analysis for NATCOPHARM based on the given parameters
📊 Swing Trade Rating: 3.6
| Stock Code | NATCOPHARM | Market Cap | 15,824 Cr. | Current Price | 884 ₹ | High / Low | 1,227 ₹ |
| Stock P/E | 12.4 | Book Value | 478 ₹ | Dividend Yield | 0.68 % | ROCE | 16.6 % |
| ROE | 16.1 % | Face Value | 2.00 ₹ | DMA 50 | 1,000 ₹ | DMA 200 | 969 ₹ |
| Chg in FII Hold | 2.21 % | Chg in DII Hold | 0.07 % | PAT Qtr | 210 Cr. | PAT Prev Qtr | 107 Cr. |
| RSI | 34.3 | MACD | -66.5 | Volume | 9,83,540 | Avg Vol 1Wk | 8,55,220 |
| Low price | 789 ₹ | High price | 1,227 ₹ | PEG Ratio | 0.45 | Debt to equity | 0.08 |
| 52w Index | 21.6 % | Qtr Profit Var | -51.0 % | EPS | 71.6 ₹ | Industry PE | 32.1 |
NATCOPHARM shows fair potential for swing trading. The current price of 884 ₹ is below both the 50 DMA (1,000 ₹) and 200 DMA (969 ₹), indicating short-term weakness. RSI at 34.3 suggests oversold conditions, while MACD at -66.5 reflects bearish momentum. Fundamentals remain solid with ROE at 16.1%, ROCE at 16.6%, and EPS of 71.6 ₹. Valuation is attractive (P/E 12.4 vs industry 32.1, PEG 0.45), but recent profit decline (-51% QoQ) raises caution.
Optimal Entry Price: 860–890 ₹ (near current support).
Exit Strategy if Holding: Consider profit booking around 980–1,020 ₹. If momentum sustains, monitor for breakout toward 1,227 ₹ resistance.
✅ Positive
- 📈 Attractive valuation (P/E 12.4 vs industry 32.1).
- 💰 Low debt-to-equity ratio (0.08) ensures financial stability.
- 📊 EPS of 71.6 ₹ reflects strong earnings power.
- 📈 FII holding increased (+2.21%), showing foreign investor confidence.
⚠️ Limitation
- 📉 Current price below both 50 DMA and 200 DMA indicates weak technical trend.
- 📊 RSI at 34.3 suggests oversold but also weak momentum.
- 📉 Dividend yield of 0.68% is modest.
🚨 Company Negative News
- 📉 Quarterly PAT dropped sharply (210 Cr. vs 107 Cr. previously, -51% variation).
🌟 Company Positive News
- 📈 EPS of 71.6 ₹ supports investor confidence.
- 💹 Strong FII inflows (+2.21%) highlight foreign interest.
🏭 Industry
- 📊 Industry P/E at 32.1 is much higher, showing NATCOPHARM trades at a discount.
- 💊 Pharma sector remains resilient, supported by healthcare demand and exports.
📌 Conclusion
NATCOPHARM is a fair candidate for swing trading with strong fundamentals and attractive valuation. Entry near 860–890 ₹ offers a good risk-reward setup. Exit should be considered around 980–1,020 ₹ unless momentum sustains toward 1,227 ₹. Traders should monitor RSI and quarterly earnings closely before entry.
Would you like me to extend this by benchmarking NATCOPHARM against peers like Sun Pharma, Dr_Reddy's, or Cipla to highlight relative swing trade opportunities?